Shanghai Medicilon Inc (688202.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100003NQ8
Shanghai Medicilon Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.04 bn CNY | 1.16 bn CNY |
| Gross profit | 65.47 m CNY | 201.88 m CNY |
| Operating income | -216.43 m CNY | -97.75 m CNY |
| EBIT | -372.71 m CNY | -175.49 m CNY |
| Net income | -330.85 m CNY | -167.83 m CNY |
| Diluted EPS – continuing operations | -2.46 CNY | -1.25 CNY |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, safety assessment, IND-Enabling studies, and advanced technology services. The company also provides peptide, SiRNA, ADC, Protac, AOCs, NAMs Platforms. The company was founded in 2004 and is based in Shanghai, China.
More stocks
- Yubico AB (YUBICO.ST)
- FLOWERS FOODS INC (FLO)
- Aliaxis SA (BE0941243520.BR)
- Fevertree Drinks PLC (FEVR.L)
- Sesa SpA (SES.MI)
- Grand City Properties SA (GYC.DE)
- Butterfly Network, Inc. (BFLY)
- Linea Directa Aseguradora SA Compania de Seguros y Reaseguros (LDA.MC)
- ALPEK S.A.B. de C.V (ALPEKA.MX)
- ChipMOS Technologies Inc (IMOS)
- Hyundai Green Food Co Ltd (005440.KS)
- MR. D.I.Y. Holding (Thailand) Public Company Limited (MRDIYT.BK)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.